1. Home
  2. ANAB vs CAL Comparison

ANAB vs CAL Comparison

Compare ANAB & CAL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ANAB

AnaptysBio Inc.

HOLD

Current Price

$44.88

Market Cap

1.2B

Sector

Health Care

ML Signal

HOLD

Logo Caleres Inc.

CAL

Caleres Inc.

HOLD

Current Price

$13.26

Market Cap

382.4M

ML Signal

HOLD

Company Overview

Basic Information
Metric
ANAB
CAL
Founded
2005
1878
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Shoe Manufacturing
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
382.4M
IPO Year
2017
N/A

Fundamental Metrics

Financial Performance
Metric
ANAB
CAL
Price
$44.88
$13.26
Analyst Decision
Buy
Hold
Analyst Count
11
1
Target Price
$61.40
$14.00
AVG Volume (30 Days)
560.8K
1.2M
Earning Date
11-04-2025
12-09-2025
Dividend Yield
N/A
2.10%
EPS Growth
N/A
N/A
EPS
N/A
0.62
Revenue
$169,467,000.00
$2,702,018,000.00
Revenue This Year
$135.45
$1.74
Revenue Next Year
N/A
$5.85
P/E Ratio
N/A
$21.55
Revenue Growth
196.42
N/A
52 Week Low
$12.21
$9.54
52 Week High
$47.86
$27.11

Technical Indicators

Market Signals
Indicator
ANAB
CAL
Relative Strength Index (RSI) 67.45 58.80
Support Level $42.80 $11.09
Resistance Level $47.86 $13.54
Average True Range (ATR) 2.40 0.77
MACD 0.14 0.20
Stochastic Oscillator 65.87 81.61

Price Performance

Historical Comparison
ANAB
CAL

About ANAB AnaptysBio Inc.

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

About CAL Caleres Inc.

Caleres Inc is a footwear company that operates retail shoe stores and e-commerce websites, and designs, develops, sources, manufactures, and distributes footwear for people of all ages. The Company's business operations are organized into two reportable segments - famous Footwear and Brand Portfolio. The famous Footwear segment is comprised of its famous Footwear retail stores, famousfootwear.com, and famousfootwear.ca. The famous Footwear segment operated around 846 stores at the end of 2024. The Brand Portfolio segment offers retailers and consumers a cultivated portfolio of known brands. Geographically, the company generates the majority of its revenue from Domestic operations.

Share on Social Networks: